Evaxion Biotech A/S(EVAX)Earnings, Financials & Key Ratios
EVAX•NASDAQ
Price updated Jun 19, 2026
AboutEvaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.Show more
- Revenue$8M+125.1%
- EBITDA-$9M+39.0%
- Net Income-$8M+27.1%
- EPS (Diluted)-1.21+87.7%
- Gross Margin100%
- EBITDA Margin-114.49%+72.9%
- Operating Margin-122.66%+72.2%
- Net Margin-102.38%+67.6%
- ROE-100.18%
EVAX Key Insights
Evaxion Biotech A/S (EVAX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 14 (bottom 14%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EVAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EVAX Price & Volume
Evaxion Biotech A/S (EVAX) stock price & volume — 10-year historical chart
Loading chart...
EVAX Growth Metrics
Evaxion Biotech A/S (EVAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM125.15%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM27.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM80.98%
Return on Capital
10 Years-315.78%
5 Years-133.44%
3 Years-151.11%
Last Year-57.23%
EVAX Peer Comparison
Evaxion Biotech A/S (EVAX) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NEON | 18.8M | 1.12 | 2.20 | -33.66% | 386.64% | 38.45% | 0.02 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 IOVA | 1.4B | 3.91 | -3.59 | 60.6% | -123.9% | -50.17% | 0.07 | |
 GILD | 153.66B | 123.76 | 18.25 | 2.39% | 30.99% | 42.33% | 1.09 | |
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 MRNA | 25.37B | 63.96 | -8.81 | -39.23% | -143.55% | -36.73% | 0.22 | |
 BNTX | 22.98B | 90.89 | -17.51 | 0.2% | -39.6% | -6.03% | 0.01 |
Compare EVAX vs Peers
Evaxion Biotech A/S (EVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EVAX Income Statement
Evaxion Biotech A/S (EVAX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 73K | 3.34M | 7.53M |
Revenue Growth % | - | - | - | - | - | - | 4480.82% | 125.12% |
Cost of Goods Sold | 73.93K | 80.98K | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | -73.93K▲ 0% | -80.98K▼ 9.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 73K▲ 0% | 3.34M▲ 4480.8% | 7.53M▲ 125.1% |
Gross Margin % | - | - | - | - | - | 100% | 100% | 100% |
Gross Profit Growth % | - | -9.54% | 100% | - | - | - | 4480.82% | 125.12% |
Operating Expenses | 5.63M | 11.28M | 16.57M | 25.83M | 25.26M | 22.27M | 18.08M | 16.76M |
OpEx % of Revenue | - | - | - | - | - | 30506.85% | 540.55% | 222.66% |
Selling, General & Admin | 1.88M | 2.63M | 5.67M | 6.18M | 8.06M | 10.08M | 7.32M | 6.49M |
SG&A % of Revenue | - | - | - | - | - | 13806.85% | 218.81% | 86.16% |
Research & Development | 3.73M | 8.65M | 11.7M | 19.58M | 17.06M | 11.92M | 10.46M | 9.97M |
R&D % of Revenue | - | - | - | - | - | 16323.29% | 312.71% | 132.51% |
Other Operating Expenses | 15K | 0 | -800K | 71K | 144K | 275K | 302K | 301K |
Operating Income | -5.63M▲ 0% | -11.36M▼ 101.9% | -16.57M▼ 45.8% | -25.83M▼ 55.9% | -25.26M▲ 2.2% | -22.2M▲ 12.1% | -14.73M▲ 33.6% | -9.23M▲ 37.3% |
Operating Margin % | - | - | - | - | - | -30406.85% | -440.55% | -122.66% |
Operating Income Growth % | - | -101.9% | -45.84% | -55.93% | 2.21% | 12.14% | 33.63% | 37.32% |
EBITDA | -5.55M | -11.28M | -16.46M | -25.49M | -24.69M | -21.58M | -14.13M | -8.62M |
EBITDA Margin % | - | - | - | - | - | -29564.38% | -422.4% | -114.49% |
EBITDA Growth % | - | -103.13% | -45.95% | -54.83% | 3.13% | 12.6% | 34.55% | 38.98% |
D&A (Non-Cash Add-back) | 73.93K | 80.98K | 105K | 344K | 571K | 615K | 607K | 615K |
EBIT | -6.25M | -11.98M | -16.57M | -24.55M | -23.14M | -22.02M | -10.39M | -7.74M |
Net Interest Income | -696K | -1.21M | -7K | 1.12M | 1.32M | -743K | -708K | -577K |
Interest Income | 2K | 9K | 216K | 2.04M | 2.83M | 154K | 254K | 299K |
Interest Expense | 698K | 1.22M | 223K | 915K | 1.51M | 897K | 962K | 876K |
Other Income/Expense | -636.93K | -656.87K | -7K | 1.12M | 1.32M | -718K | 3.38M | 619K |
Pretax Income | -6.27M▲ 0% | -12.02M▼ 91.7% | -16.57M▼ 37.9% | -24.71M▼ 49.1% | -23.94M▲ 3.1% | -22.91M▲ 4.3% | -11.36M▲ 50.4% | -8.62M▲ 24.1% |
Pretax Margin % | - | - | - | - | - | -31390.41% | -339.56% | -114.44% |
Income Tax | -735K | -824.84K | -1.56M | -178K | -772K | -790K | -788K | -908K |
Effective Tax Rate % | 11.72% | 6.86% | 9.39% | 0.72% | 3.22% | 3.45% | 6.94% | 10.54% |
Net Income | -5.54M▲ 0% | -11.19M▼ 102.2% | -15.02M▼ 34.2% | -24.53M▼ 63.4% | -23.17M▲ 5.6% | -22.13M▲ 4.5% | -10.57M▲ 52.2% | -7.71M▲ 27.1% |
Net Margin % | - | - | - | - | - | -30308.22% | -316% | -102.38% |
Net Income Growth % | - | -102.22% | -34.18% | -63.35% | 5.56% | 4.51% | 52.24% | 27.07% |
Net Income (Continuing) | -5.53M | -11.19M | -15.02M | -24.53M | -23.17M | -22.13M | -10.57M | -7.71M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -11.52▲ 0% | -27.60▼ 139.6% | -37.00▼ 34.1% | -50.40▼ 36.2% | -39.20▲ 22.2% | -32.40▲ 17.3% | -9.80▲ 69.8% | -1.21▲ 87.7% |
EPS Growth % | - | -139.58% | -34.06% | -36.22% | 22.22% | 17.35% | 69.75% | 87.65% |
EPS (Basic) | -11.52 | -27.60 | -37.00 | -50.40 | -39.20 | -32.40 | -9.80 | -1.21 |
Diluted Shares Outstanding | 479.97K | 404.97K | 404.97K | 487.33K | 590.97K | 683.39K | 1.07M | 6.41M |
Basic Shares Outstanding | 479.97K | 404.97K | 404.97K | 487.33K | 590.97K | 683.39K | 1.07M | 6.41M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
EVAX Balance Sheet
Evaxion Biotech A/S (EVAX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 8.38M | 10.96M | 10.95M | 34.7M | 16.98M | 8.35M | 8.77M | 24.9M |
Cash & Short-Term Investments | 7.43M | 9.56M | 5.83M | 32.17M | 13.18M | 5.58M | 5.05M | 23.23M |
Cash Only | 7.43M | 9.56M | 5.83M | 32.17M | 13.18M | 5.58M | 5.05M | 23.23M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 772K | 0 | 0 | 0 | 0 | 0 | 1.86M | 1.05M |
Days Sales Outstanding | - | - | - | - | - | - | 202.8 | 50.96 |
Inventory | -1.36M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 931K | 3.94M | 1.9M | 1.31M | 1.07M | 900K | 0 |
Total Non-Current Assets | 130K | 126K | 1.01M | 5.46M | 5.04M | 4.54M | 3.72M | 3.51M |
Property, Plant & Equipment | 130K | 101K | 221K | 5.17M | 4.67M | 4.34M | 3.51M | 3.32M |
Fixed Asset Turnover | - | - | - | - | - | 0.02x | 0.95x | 2.27x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 100K | 93K | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 44K | 0 |
Other Non-Current Assets | 0 | 25K | 694K | 191K | 365K | 196K | 162K | 185K |
Total Assets | 8.51M▲ 0% | 11.08M▲ 30.2% | 11.96M▲ 7.9% | 40.16M▲ 235.7% | 22.02M▼ 45.2% | 12.89M▼ 41.5% | 12.48M▼ 3.1% | 28.41M▲ 127.5% |
Asset Turnover | - | - | - | - | - | 0.01x | 0.27x | 0.27x |
Asset Growth % | - | 30.2% | 7.95% | 235.67% | -45.16% | -41.48% | -3.13% | 127.53% |
Total Current Liabilities | 9.42M | 1.72M | 4.93M | 4.32M | 3.76M | 7.08M | 4.37M | 4.26M |
Accounts Payable | 139K | 646K | 3.67M | 2.85M | 2.08M | 2.69M | 2.97M | 2.19M |
Days Payables Outstanding | 686.28 | 2.91K | - | - | - | - | - | - |
Short-Term Debt | 8.57M | 0 | 0 | 126K | 136K | 159K | 159K | 549.99K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 440K | 177K | 180K | 46K | 885K | 3.02M | 927K | 416K |
Current Ratio | 0.89x | 6.36x | 2.22x | 8.03x | 4.51x | 1.18x | 2.01x | 5.85x |
Quick Ratio | 1.03x | 6.36x | 2.22x | 8.03x | 4.51x | 1.18x | 2.01x | 5.85x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 24K | 0 | 0 | 3.4M | 9.96M | 10.53M | 9.77M | 7.11M |
Long-Term Debt | 0 | 0 | 0 | 1.04M | 7.86M | 8.49M | 8.01M | 5.35M |
Capital Lease Obligations | 24K | 0 | 0 | 2.21M | 1.95M | 1.9M | 1.62M | 1.61M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 153K | 144K | 149K | 141K | 158K |
Total Liabilities | 9.44M | 1.72M | 4.93M | 7.73M | 13.72M | 17.62M | 14.14M | 11.37M |
Total Debt | 8.67M | 36K | 20K | 3.69M | 10.26M | 10.87M | 10.1M | 7.5M |
Net Debt | 1.24M | -9.52M | -5.81M | -28.48M | -2.93M | 5.29M | 5.05M | -15.73M |
Debt / Equity | - | 0.00x | 0.00x | 0.11x | 1.24x | - | - | 0.44x |
Debt / EBITDA | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - |
Interest Coverage | -8.95x | -9.80x | -74.30x | -26.83x | -15.35x | -24.55x | -10.80x | -8.83x |
Total Equity | -931K▲ 0% | 9.36M▲ 1105.6% | 7.04M▼ 24.8% | 32.44M▲ 360.9% | 8.3M▼ 74.4% | -4.73M▼ 157.0% | -1.65M▲ 65.1% | 17.04M▲ 1131.4% |
Equity Growth % | - | 1105.59% | -24.82% | 360.88% | -74.4% | -156.96% | 65.07% | 1131.4% |
Book Value per Share | -1.94 | 23.12 | 17.38 | 66.56 | 14.05 | -6.92 | -1.54 | 2.66 |
Total Shareholders' Equity | -931K | 9.36M | 7.04M | 32.44M | 8.3M | -4.73M | -1.65M | 17.04M |
Common Stock | 2.11M | 2.48M | 2.65M | 3.75M | 3.89M | 5.9M | 10.52M | 15.79M |
Retained Earnings | -6.98M | -15.81M | -27.28M | -50.43M | -85.84M | -107.97M | -118.54M | -126.24M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 3.94M | -169K | 226K | -1.32M | 9.53M | 9.89M | -3.6M | 6.76M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EVAX Cash Flow Statement
Evaxion Biotech A/S (EVAX) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.99M | -7.02M | -12.44M | -21.93M | -25.77M | -17.69M | -12.94M | -6.65M |
Operating CF Margin % | - | - | - | - | - | -24234.25% | -386.96% | -88.27% |
Operating CF Growth % | - | -252.54% | -77.2% | -76.34% | -17.51% | 31.36% | 26.86% | 48.65% |
Net Income | -5.54M | -11.2M | -15.02M | -24.53M | -23.17M | -22.13M | -10.57M | -7.73M |
Depreciation & Amortization | 74K | 81K | 105K | 344K | 571K | 615K | 607K | 616.88K |
Stock-Based Compensation | 2.07M | 2.36M | 3.41M | 1.38M | 942K | 479K | 357K | 0 |
Deferred Taxes | -735K | -825K | -2.07M | -190K | -998K | -984K | -813K | 0 |
Other Non-Cash Items | 1.16M | 1.99M | 919K | -171K | -243K | 2.76M | -3.04M | 605.85K |
Working Capital Changes | 981K | 573K | 215K | 1.24M | -2.88M | 1.56M | 520K | -137.42K |
Change in Receivables | 443K | -337K | -2.5M | 1.86M | -1.49M | 1.11M | 374K | 178.54K |
Change in Inventory | 446K | 0 | 0 | 0 | 1.49M | 0 | 0 | 0 |
Change in Payables | 79K | 507K | 1.8M | -647K | -599K | 502K | 449K | -537.64K |
Cash from Investing | 6K | -68K | -393K | -1.33M | -268K | -93K | -3K | -14.04K |
Capital Expenditures | -7K | -68K | -358K | -1.3M | -292K | -87.13K | 0 | -11.03K |
CapEx % of Revenue | - | - | - | - | - | 119.36% | - | 0.15% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 13K | 0 | -35K | -60K | -13 | 133 | 0 | 0 |
Cash from Financing | 9.03M | 9.51M | 8.82M | 49.8M | 7.85M | 10.69M | 13.13M | 22.48M |
Debt Issued (Net) | 7.93M | 79K | -74K | -289K | 7.42M | -632K | -1.14M | -400.22K |
Equity Issued (Net) | 1.09M | 9.44M | 9.02M | 53.85M | 428K | 9.17M | 16.55M | 23.23M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -13K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | -13K | -128K | -3.76M | 0 | 2.15M | -2.29M | -353.08K |
Net Change in Cash | 6.96M▲ 0% | 2.13M▼ 69.5% | -3.73M▼ 275.2% | 26.33M▲ 806.9% | -18.98M▼ 172.1% | -7.6M▲ 60.0% | 369K▲ 104.9% | 17.28M▲ 4583.3% |
Free Cash Flow | -2M▲ 0% | -7.09M▼ 254.7% | -12.83M▼ 81.0% | -23.29M▼ 81.5% | -26.07M▼ 11.9% | -17.78M▲ 31.8% | -12.94M▲ 27.2% | -6.66M▲ 48.6% |
FCF Margin % | - | - | - | - | - | -24353.42% | -386.96% | -88.42% |
FCF Growth % | - | -254.7% | -81.05% | -81.54% | -11.9% | 31.8% | 27.21% | 48.56% |
FCF per Share | -4.16 | -17.50 | -31.68 | -47.80 | -44.11 | -26.01 | -12.06 | -1.04 |
FCF Conversion (FCF/Net Income) | 0.36x | 0.63x | 0.83x | 0.89x | 1.11x | 0.80x | 1.22x | 0.86x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EVAX Key Ratios
Evaxion Biotech A/S (EVAX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -265.52% | -183.15% | -124.29% | -113.74% | -1238.11% | - | -100.18% |
Return on Invested Capital (ROIC) | -1388.24% | -11916.88% | -2337.91% | -747.37% | -405.96% | -561.29% | -558.74% | -294.33% |
Gross Margin | - | - | - | - | - | 100% | 100% | 100% |
Net Margin | - | - | - | - | - | -30308.22% | -316% | -102.38% |
Debt / Equity | - | 0.00x | 0.00x | 0.11x | 1.24x | - | - | 0.44x |
Interest Coverage | -8.95x | -9.80x | -74.30x | -26.83x | -15.35x | -24.55x | -10.80x | -8.83x |
FCF Conversion | 0.36x | 0.63x | 0.83x | 0.89x | 1.11x | 0.80x | 1.22x | 0.86x |
Revenue Growth | - | - | - | - | - | - | 4480.82% | 125.12% |
Related:EVAX Dividend History·EVAX Revenue History·EVAX Price History·EVAX P/E History·EVAX Financial Ratios·EVAX Institutional Holders
EVAX Frequently Asked Questions
Evaxion Biotech A/S (EVAX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Evaxion Biotech A/S (EVAX) reported $7.5M in revenue for fiscal year 2025.
Evaxion Biotech A/S (EVAX) grew revenue by 125.1% over the past year. This is strong growth.
Evaxion Biotech A/S (EVAX) reported a net loss of $7.7M for fiscal year 2025.
Dividend & Returns
Evaxion Biotech A/S (EVAX) has a return on equity (ROE) of -100.2%. Negative ROE indicates the company is unprofitable.
Evaxion Biotech A/S (EVAX) had negative free cash flow of $6.7M in fiscal year 2025, likely due to heavy capital investments.